LumiraDx up as UK health agency approves COVID-19, RSV tests

LumiraDx

21/06/2023 11:05

** LumiraDx Limited's shares  LMDX.O  rise 38.1% to $0.48 -
biggest gainer across U.S. stock exchanges premarket 
    ** Co said the UK's health agency has validated its COVID-19
and RSV tests under the Coronavirus Test Device Approvals (CTDA)
process
    ** Medical test maker said the test allows for detection of
SARS-CoV-2 infection within 5 minutes, which will aid the UK
government in preparing for another respiratory season 
     ** Co expects to begin commercialisation of these tests in
the UK and commence commercial shipments imminently
    ** Up to Tuesday's close, stock had fallen ~61% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))